Information Library
Results for: Australia and New Zealand - New Zealand
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
The Contribution of Early-phase Clinical Data to a Drug’s Integrated Cardiac Safety Portfolio
Hear from the Experts — December 6, 2011
This article examines the financial and time benefits to incorporating intensive ECG and QT/QTc monitoring in early-phase clinical studies. -
Energizing Enrollment
Case Study — October 4, 2011
The rapid recruitment for this Phase III, open, randomized, controlled, multi-center study in adjuvant triple-negative breast cancer (TNBC) was completed two months earlier than planned. -
Model-Based Drug Development
Brochure — October 4, 2011
Our industry-leading model-based drug development services boost the probability of success in the New Health by enabling you to make critical decisions earlier, optimizing your resources and returns. -
Polish Pharmaceutical and Healthcare Sector
Media Coverage — September 9, 2011
To say ‘Sleeping Giant’ about Poland is no longer true claims Wojciech Przybys, VP EMEA and provides a deeper analysis of the polish clinical research -
Australia and New Zealand Phase II/III Fact Sheet
Brochure — June 24, 2011
Australia and New Zealand fact sheet around Phase II/III trials. Same language. Same technology. Same quality standards. -
Digital Pathology Central Laboratory Services Fact Sheet
Brochure — June 23, 2011
This fact sheet highlights Quintiles' digital pathology services, covering everything from scanning of slides to review and analysis - giving you a faster, easier way to scan and share this critical research data. -
Genomics Fact Sheet
Brochure — June 17, 2011
Approximately 20% of today’s U.S. Clinical Trials use genomic technology. Find out about Quintiles’ offerings in this area. -
Advancing Vaccine Development in Australia and New Zealand
Case Study — April 11, 2011
Quintiles rose to the challenge of a very aggressive vaccine recruitment timeline during the holiday period - and recruited 3,000+ subjects from 18-90 years of age within just 17 days - 25 days ahead of schedule. -
Scientific Bulletin Flow Cytometry
Case Study — February 9, 2011
Quintiles has expertise in running highly regulated flow cytometry assays, as well as a number of esoteric assays, such as multicolor cell surface and intracellular staining assays, and receptor occupancy/competitive binding assays. -
Parkinson's Disease - Ambitious Recruitment
Case Study — February 1, 2011
Quintiles provided project management, clinical monitoring, and more for a study of a drug for patients with early stage idiopathic Parkinson’s disease.